uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding.
Mentions
8 mentions · latest on 22 Aug 2026
| The No Pile | - | 22 Aug 2026 | |
| Replimune recieves accelerated approval | - | 7 Aug 2026 | |
| Giles Capital Reads - Week 30 | - | 29 Jul 2026 | |
| Yet Another Value PodcastPodcast | July 2026 Random Ramblings | - | 27 Jul 2026 |
| War Cap Q2 2026 update | - | 21 Jul 2026 | |
| Value Hive PodcastPodcast | Peter Mantas: The Biotech Bubble Whisperer | - | 19 Jun 2026 |
| The Business BrewPodcast | Another FDA vs uniQure Episode | Watch video | 7 May 2026 |
| Warden 2025 year end letter | - | 1 Feb 2026 |